Detalles de la búsqueda
1.
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
N Engl J Med
; 377(20): 1930-1942, 2017 11 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-29105594
2.
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
Kidney Int
; 96(1): 159-169, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30898339
3.
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
Nephrol Dial Transplant
; 33(3): 477-489, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28379536
4.
Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
Nephrol Dial Transplant
; 33(4): 645-652, 2018 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28992127
5.
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
J Am Soc Nephrol
; 28(5): 1592-1602, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27920153
6.
Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.
Am J Kidney Dis
; 69(2): 210-219, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27856088
7.
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
Am J Nephrol
; 45(3): 257-266, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28166521
8.
Prevalence of autosomal dominant polycystic kidney disease in the European Union.
Nephrol Dial Transplant
; 32(8): 1356-1363, 2017 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27325254
9.
Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic Kidneys.
J Digit Imaging
; 30(4): 442-448, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28550374
10.
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
Nephrol Dial Transplant
; 32(7): 1262, 2017 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28444221
11.
A small molecule inhibitor of endoplasmic reticulum oxidation 1 (ERO1) with selectively reversible thiol reactivity.
J Biol Chem
; 285(27): 20993-1003, 2010 Jul 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-20442408
12.
Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress.
Mol Cell Biol
; 26(24): 9517-32, 2006 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17030613
13.
Standardizing total kidney volume measurements for clinical trials of autosomal dominant polycystic kidney disease.
Clin Kidney J
; 12(1): 71-77, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30746130
14.
Activating transcription factor 4 is translationally regulated by hypoxic stress.
Mol Cell Biol
; 24(17): 7469-82, 2004 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-15314157
15.
Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
Cancer Med
; 6(4): 723-729, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28251822
16.
Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4.
Kidney Int Rep
; 2(6): 1132-1140, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29270521
17.
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
Clin J Am Soc Nephrol
; 11(5): 803-811, 2016 05 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26912543
18.
Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial.
Kidney Int Rep
; 1(4): 213-220, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29142926
19.
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database.
Drug Saf
; 38(11): 1103-13, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26188764
20.
Internal ribosome entry site-mediated translation of Apaf-1, but not XIAP, is regulated during UV-induced cell death.
J Biol Chem
; 281(22): 15155-63, 2006 Jun 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-16595687